Safety and Immunogenicity of Fully Liquid Hexavalent DTaP-IPV-HepB-Hib Vaccine in Healthy Infants in Russian Federation

Relevance/aims: Multivalent vaccines are crucial in the control of diseases including diphtheria (D), tetanus (T), pertussis (P), polio, hepatitis B (HB), and Haemophilus influenzae type b (Hib [PRP~T]). To evaluate the safety and immunogenicity of a fully liquid, hexavalent DTaP-IPV-HB-PRP~Tvaccine in infants in the Russian Federation.

Materials & methods. Infants (N=100) who had received a standalone HB vaccine within 24 hours after birth and at 1 month of age and a pentavalent (DTaP-IPV/PRP~T) vaccine at 3 and 4.5 months of age were enrolled and received the hexavalent DTaP-IPV-HB-PRP~T vaccine at 6 months of age. Safety was assessed from parental reports and immunogenicity using validated assays.

Results. There were no safety concerns, with 38.0% and 49.0% of participants experiencing ≥ 1 solicited injection site and ≥ 1 solicited systemic reaction within 7 days after vaccination, respectively, and 16.0% reporting an unsolicited adverse event (AE) within 30 days after vaccination. The incidence of each solicited reaction with severity Grade 3 was ≤6.0% and all unsolicited AEs were Grade 1 or 2. Most AEs started ≤ 3 days post-vaccination, were short-lived, and resolved spontaneously. There were no serious AEs. On month post-vaccination 100.0% of participants had antibodies ≥ 10 mIU/ mL for anti-HBs, ≥ 0.01 IU/mL for anti-D and anti-T, ≥8 (1/dil) for anti-polio-1,2, 3, and 97.9% of participants had anti-PRP antibodies ≥ 0.15 gg/ml. For anti-PT and anti-FHA, GMCs were in the expected range.

Conclusion. These results support vaccination with the DTaP-IPV-HB-PRP~T vaccine in the Russian Federation following the recommended national immunization schedule.

1. Decker MD, Edwards KM, Howe BJ. Combination vaccines. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM, editors. Vaccines. 7th ed. PA, USA: Elsevier; 2018. P. 198-227.

2. Bar-On ES, Goldberg E, Hellmann S, Leibovici L. Combined DTP-HBV-HIB vaccine versus separately administered DTP-HBV and HIB vaccines for primary prevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae B (HIB). The Cochrane Database of Systematic Reviews. 2012(4):CD005530.

3. Robbins JB, Schneerson R, Keith JM, et al. Pertussis vaccine: a critique. The Pediatric Infectious Disease Journal. 2009;28(3):237-41.

4. Edwards KM, Decker MD. Pertussis vaccines. In: Plotkin SA, Orenstein WA, OffitPA, Edwards KM, editors. Vaccines. 7th ed. PA, USA: Elsevier; 2018. P. 711-61.

5. WHO. Pertussis vaccines: WHO position paper - September 2015. Weekly Epidemiological Record. 2015;90(35):433-58.

6. WHO. Polio vaccines: WHO position paper - March 2016. Weekly Epidemiological Record. 2016;91(12):145-68.

7. Maman K, Zollner Y, Greco D, et al. The value of childhood combination vaccines: from beliefs to evidence. Human Vaccines & Immunotherapeutics. 2015;11(9):2132-41.

8. Plotkin SA, Liese J, Madhi SA, et al. A DTaP-IPV//PRP~T vaccine (Pentaxim): a review of 16 years' clinical experience. Expert Review of Vaccines. 2011;10(7):981-1005.

9. Novikova D, Namazova-Baranova L, Gayvoronskaya A, et al. Safety analysis for pentavaccine used in premature infants. Current Pediatrics. 2015;14(3):392-5. (In Russ.)

10. WHO. WHO prequalified vaccines 2018. Available at: https://extranet.who.int/gavi/PQ_Web/ Accessed: 02 Nov 2018.

11. Tregnaghi MW, Voelker R, Santos-Lima E, et al. Immunogenicity and safety of a novel yeast Hansenula polymorpha-derived recombinant Hepatitis B candidate vaccine in healthy adolescents and adults aged 10-45years. Vaccine. 2010;28(20):3595-601.

12. Vesikari T, Silfverdal SA, Jordanov E, et al. A randomized, controlled study of DTaP-IPV-HB-PRP-T, a fully liquid hexavalent vaccine, administered in a 3, 5 and 11-12 month schedule. The Pediatric Infectious Disease Journal. 2017;36(1):87-93.

13. Aquino AG, Brito MG, Doniz CE, et al. A fully liquid DTaP-IPV-Hep B-PRP-T hexavalent vaccine for primary and booster vaccination of healthy Mexican children. Vaccine. 2012;30(45):6492-500.

14. Kosalaraksa P, Thisyakorn U, Benjaponpitak S, et al. Immunogenicity and safety study of a new DTaP-IPV-Hep B-PRP-T combined vaccine compared to a licensed DTaP-IPV-Hep B//PRP-T comparator, both concomitantly administered with a 7-valent pneumococcal conjugate vaccine at 2, 4, and 6 months of age in Thai infants. International Journal of Infectious Diseases. 2011;15(4):e249-56.

15. Lanata C, Zambrano B, Ecker L, et al. Immunogenicity and safety of a fully liquid DTaP-IPV-Hep B-PRP-T vaccine at 2-4-6 months of age in Peru. Journal of Vaccines and Vaccination. 2012;3:128.

16. Macias M, Lanata CF, Zambrano B, et al. Safety and immunogenicity of an investigational fully liquid hexavalent DTaP-IPV-Hep B-PRP-T vaccine at two, four and six months of age compared with licensed vaccines in Latin America. The Pediatric Infectious Disease Journal. 2012;31(8):e126-32.

17. Lopez P, Mohs A, Vdsquez A, et al. A randomized, controlled study of a fully liquid DTaP-IPV-HB-PRP-T hexavalent vaccine for primary and booster vaccinations of healthy infants and toddlers in Latin America. The Pediatric Infectious Disease Journal. 2017;36(11):e272-e82.

18. Ceyhan M, Yildirim I, Tezer H, et al. A fully liquid DTaP-IPV-HB-PRP-T hexavalent vaccine for primary and booster vaccination of healthy Turkish infants and toddlers. Turkish Journal of Medical Sciences. 2017;47:1247-56.

19. Feroldi E, Prymula R, Kieninger D, et al. Immunogenicity/safety of a hexavalent DTaP-IPV-HB-Hib vaccine versus Infanrix®Hexa concomitantly administered with Prevenar13® and RotaTeq® at 2,3,4 months of age in European infants. 34th European Society for Pediatric Infectious Diseases (ESPID), Brighton, UK, 10-14 May 2016 (Poster).

20. Chhatwal J, Lalwani S, Vidor E. Immunogenicity and safety of a liquid hexavalent vaccine in Indian infants. Indian Pediatrics. 2017;54:15-20.

21. Madhi SA, Mitha I, Cutland C, et al. Immunogenicity and safety of an investigational fully liquid hexavalent combination vaccine versus licensed combination vaccines at 6, 10, and 14 weeks of age in healthy South African infants. The Pediatric Infectious Disease Journal. 2011;30(4):e68-74.

22. Order of Ministry of Health of Russian Federation No. 125n dated 21.03.2014. On approval of national calendar of prophylactic vaccines and calendar of prophylactic vaccines for epidemic indications. Available at: http://base.garant.ru/70647158 Accessed 15 June 2018. (In Russ.)

23. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Statistics in Medicine. 1998;17(8):857-72.

24. Lyseng-Williamson K, McCormack PL. DTaP-IPV-Hep B-Hib vaccine (Hexyon®/Haxacima®): a guide to its use in the primary and booster vaccination of infants and toddlers in Europe. Drugs & Therapy Perspectives. 2013;29(11):329-35.

25. McCormack PL. DTaP-IPV-Hep B-Hib vaccine (Hexaxim®): a review of its use in primary and booster vaccination. Paediatric Drugs. 2013;15(1):59-70.

26. Santos-Lima E, B'Chir S, Lane A. Combined immunogenicity data for a new DTaP-IPV-Hep B-PRP-T vaccine (Hexaxim) following primary series administration at 2,4,6 months of age in Latin America. Vaccine. 2013;31(9):1255-8.

27. Tregnaghi MW, Zambrano B, Santos-Lima E. Immunogenicity and safety of an investigational hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-hepatitis B-Haemophilus influenzae B conjugate combined vaccine in healthy 2-, 4-, and 6-month-old Argentinean infants. The Pediatric Infectious Disease Journal. 2011;30(6):e88-96.

28. Kim YK, Vidor E, Kim HM, et al. Immunogenicity and safety of a fully liquid DTaP-IPV-HB-PRP~Thexavalent vaccine compared with the standard of care in infants in the Republic of Korea. Vaccine. 2017;35(32):4022-8.

29. Martinon-Torres F, Diez-Domingo J, Feroldi E, et al. Immunogenicity/safety of a DTaP-backboned hexavalent/pentavalent/hexavalent sequential schedule at 2,4,6 months of age in European infants. 34th European Society for Pediatric Infectious Diseases (ESPID), Brighton, UK, 10-14 May 2016 (Poster).

30. Tregnaghi M, Zambrano B, Santos-Lima E. Antibody persistence after a primary series of a new DTaP-IPV-Hep B-PRP-T combined vaccine or separate DTaP-IPV//PRP-T and hepatitis B vaccines at 2, 4, and 6 months of age and the effect of a subsequent DTaP-IPV//PRP-T booster vaccination at 18 months of age in healthy Argentinean infants. The Pediatric Infectious Disease Journal. 2012;31(1):e24-30.

31. Vidor E, Plotkin SA. Immunogenicity of a two-component (PT & FHA) acellular pertussis vaccine in various combinations. Human Vaccines. 2008;4(5):328-40.

32. Thisyakorn U, Montellano M, Lane A. Routine newborn hepatitis B immunization: a review of schedules. Infectious Diseases in Clinical Practice. 2011;19(5):326-31